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Abstract
Introduction: Type 2 diabetes is increasing in prevalence worldwide and is a leading cause of morbidity and mortality, mainly due to the 
development of complications. Vildagliptin is an inhibitor of dipeptidyl peptidase 4 (DPP-4), a new class of oral antidiabetic agents.
Aims: To evaluate the role of vildagliptin in the management of type 2 diabetes.
Evidence review: Clear evidence shows that vildagliptin improves glycemic control (measured by glycosylated hemoglobin and blood 
glucose levels) more than placebo in adults with type 2 diabetes, either as monotherapy or in combination with metformin. Vildagliptin 
is as effective as pioglitazone and rosiglitazone, and slightly less effective than metformin, although better tolerated. Further glycemic 
control is achieved when adding vildagliptin to metformin, pioglitazone, or glimepride. There is evidence that vildagliptin improves   
beta-cell function and insulin sensitivity. Vildagliptin does not appear to be associated with weight gain or with a higher risk of hypoglycemia 
than placebo or other commonly used oral antidiabetic agents. Economic evidence is currently lacking.
Place in therapy: Vildagliptin improves glycemic control with little if any weight gain or hypoglycemia in adult patients with type 2 
diabetes when given alone or in combination with metformin, thiazolidinediones, or sulfonylureas. Since many diabetic patients require 
combination  therapy,  the  complementary  mechanism  of  action  of  vildagliptin  and  other  commonly  prescribed  antidiabetic  drugs 
represents an important new therapeutic option in diabetes management.
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Outcome measure Evidence Implications
Disease-oriented evidence
Reduction in glycylated hemoglobin Clear Vildagliptin improves glycemic control more than placebo; 50 mg bid less effective 
than metformin 1 g bid; comparable to pioglitazone and rosiglitazone
Reduction in fasting and postprandial  
plasma glucose
Clear Greater reduction with vildagliptin than with placebo; more sustained effect than 
rosiglitazone
Glycemic control in combination with metformin, 
pioglitazone, or glimepride 
Clear Adding vildagliptin to metformin, thiazolidinediones, or sulfonylureas causes a 
further improvement in glycemic control
Increase in postprandial GLP-1 Clear Greater increase with vildagliptin than placebo
Effects on postprandial insulin Substantial Similar with vildagliptin and placebo. Implies improved insulin secretion and 
sensitivity, shown by no change in insulin with lower glucose
Improvement in beta-cell function Clear Greater improvement with vildagliptin than placebo
Improvement in insulin sensitivity Substantial Greater improvement with vildagliptin than placebo
Patient-oriented evidence
Hypoglycemia Clear Similar frequency with vildagliptin and placebo, and with metformin  
or thiazolidinediones
Weight gain Clear Similar with vildagliptin and placebo; weight gain less than with thiazolidinediones, 
but greater than with metformin 
Tolerability Clear Well tolerated with few adverse effects; nasopharyngitis, cough, and headache
Liver function Limited Unpublished data reveal similar elevations in liver enzymes compared with 
metformin, a thiazolidinedione, a sulfonylurea, or placebo. Liver function tests 
necessary before and during treatment with vildagliptin, and the drug should not be 
used in patients with liver impairment 
Economic evidence
Cost effectiveness No evidence Studies required to verify the impact of vildagliptin alone or in combination with 
other oral agents on costs of illness
bid, twice daily; GLP-1, glucagon-like peptide.
Core evidence place in therapy summary for vildagliptin 50 mg once or twice daily in adults with 
type 2 diabetesVildagliptin | place in therapy review
Scope, aims, and objectives
Vildagliptin (Galvus®, LAF 237, Novartis) is an inhibitor of dipeptidyl 
peptidase 4 (DPP-4) that has been developed for the treatment 
of type 2 diabetes. The drug was approved for use in the EU in 
February 2008 and is available in Mexico and Brazil.
DPP-4 is a new therapeutic target for the treatment of type 2 
diabetes, and its role and the mechanism of action of vildagliptin 
are discussed in the Disease overview section below. 
This article reviews the currently available published evidence on 
the effects of vildagliptin in type 2 diabetes, and considers its 
potential for clinical and economic benefit. The primary emphasis 
is given to clinical studies, but results of preclinical and clinical 
pharmacology investigations are also summarized. 
Methods
English  language  literature  searches  were  conducted  on   
October  10,  2005  in  the  following  databases,  searching  from 
the beginning of the database to date unless otherwise stated. 
The search strategy was “(vildagliptin OR laf 237) AND diabetes” 
unless otherwise stated.
•   PubMed,  http://www.ncbi.nlm.nih.gov/entrez/query.fcgi,  1966 
to date. Search strategy, “(vildagliptin OR laf 237) AND diabetes,” 
was expanded by Automatic Term Mapping to “(((“Vildagliptin” 
[TIAB] NOT Medline[SB]) OR “Vildagliptin”[Substance Name] OR 
vildagliptin[Text Word]) OR (“1-(((3-hydroxy-1-adamantyl)amino)
acetyl)-2-cyanopyrrolidine”[Substance Name] OR laf 237[Text 
Word])) AND ((“diabetes mellitus”[TIAB] NOT Medline[SB]) OR 
“diabetes mellitus”[MeSH Terms] OR (“diabetes insipidus”[TIAB] 
NOT Medline[SB]) OR “diabetes insipidus”[MeSH Terms] OR 
diabetes[Text Word]) AND English[Lang].”
•   EMBASE, http://www.datastarweb.com, 1974 to date. Search 
strategy: “(vildagliptin OR laf 237) AND diabetes”.  
•   Database  of  Abstracts  of  Reviews  of  Effectiveness  (DARE), 
National Health Service (NHS) Economic Evaluations Database 
(NHSEED),  Health  Technology  Assessment  (HTA),  www.york.
ac.uk/inst/crd/darehp.htm. All three databases were searched 
together. All fields searched.
•   NHS HTA, www.ncchta.org. 
•   National Guideline Clearing House, www.guideline.gov.
•   National  Institute  for  Health  and  Clinical  Excellence  (NICE), 
www.nice.org.uk. 
•   Cochrane  Database  of  Systematic  Reviews  (CDSR),  www.
cochrane.org/index0.htm. Entire site searched.
•   Clinical Evidence (BMJ), www.clinicalevidence.com. 
•   www.clinicaltrials.gov.
•   www.clinicalstudyresults.org.
After removal of duplicates, a total of 69 records were identified. 
Records  were  manually  reviewed  and  61  were  excluded  for 
the  following  reasons:  nonsystematic  reviews  (n=45);  letters, 
editorials, news items, notes, comments, and corrections (n=13); 
articles about other drugs or treatments (n=2); articles on other 
subjects (n=1). Eight papers remained and were included in the 
evidence base (Table 1). 
Meeting abstracts from 2002 or later were identified by searching 
BIOSIS Previews, http://www.datastarweb.com, 1996 to date, using 
the search strategy “(vildagliptin OR laf 237) AND diabetes AND 
PT=MEETING$ AND LG=EN AND (YEAR=2002 OR YEAR=2003 
OR YEAR=2004 OR YEAR=2005).” One record was retrieved.
Abstracts from the American Diabetes Association (ADA) Scientific 
Sessions  for  2003–2005  inclusive  were  searched  online  at   
http://scientificsessions.diabetes.org/Abstracts/index.cfm  using 
a text search for the terms “vildagliptin” or “laf 237”. A further 
19 abstracts were obtained, one of which was a duplicate of the 
abstract on BIOSIS (Table 1). The manufacturer supplied citation 
details for four additional abstracts that were not available on   
the  databases  searched,  and  these  four  were  also  included   
(Table 1). This produced a total of 23 abstracts, of which three were 
excluded as duplicate presentations of data already published 
as full papers and a further four were excluded because their 
main focus was another compound, thus leaving 16 abstracts for 
inclusion (Table 1).
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Number of records
Category Full papers Abstracts
Initial search 69 19
records excluded 61 6
records included 8 13
Additional papers identified 0 0
Search update
records excluded 5 35
records included 8 12
Publications not available on 
databases and supplied by 
manufacturer
0 3a
Publications identified from 
additional sources
4 0
Level 1 clinical evidence 
(systematic review, meta analysis)
1 0
Level 2 clinical evidence (RCT) 15 13
Level ≥3 clinical evidence
trials other than RCT 1 6
case reports
Evidence from animal and  
in vitro studies
3 9
Economic evidence 0 0
Total records included 20 28
aFour were supplied but one was a duplicate of data presented in a full paper and was excluded.
For definitions of levels of evidence, see Editorial Information inside back cover or on the 
Core Evidence website (http://www.coremedicalpublishing.com).
RCT, randomized controlled trial.
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The  PubMed  literature  search  was  repeated  on  October  11, 
2007  with  search  limits  “humans,  clinical  trial,  meta-analysis, 
randomized  controlled  trial,  English  language”  and  yielded 
13 records, of which eight were included, the remainder being 
pharmacokinetic or pharmacodynamics studies. Abstracts from 
the 2006 and 2007 annual meetings of the ADA and European 
Association for the Study of Diabetes (EASD) were also searched 
and 12 were included after removal of duplicates, subanalyses, 
and out-of-scope records. Finally, four full papers were identified 
from a meta analysis (Amori et al. 2007) that were not present in 
the PubMed search.
Disease overview 
The increasing prevalence of type 2 diabetes
It  is  estimated  that  there  are  currently  approximately  194 
million  people  with  diabetes  worldwide  and  the  prevalence  is 
projected to exceed 333 million by 2025 (IDF 2005a). Over 90% 
of those affected have type 2 diabetes. Furthermore, due to its 
asymptomatic nature, a substantial proportion of individuals with 
type 2 diabetes are unaware that they have the disease (WHO 
2003). Global estimates of the number of individuals with impaired 
glucose tolerance (IGT) or impaired fasting glucose (IFG) (often 
referred to as prediabetes) are unavailable. However, the World 
Health Organization (WHO) has suggested that it is likely to be 
even greater than the number with diabetes (WHO 2003).
Type 2 diabetes usually occurs in adults over the age of 40 years 
and is associated with a number of factors, including obesity, 
family history of diabetes, physical inactivity, and race/ethnicity. 
However, over the last two decades the increasing prevalence of 
type 2 diabetes in children and adolescents has been recognized 
as a global health problem (CDC 2005a; Pinhas-Hamiel & Zeitler 
2005). Diabetes is one of the most common chronic diseases 
among  children  in  the  US  with  approximately  150  000  young 
people  under  the  age  of  18  years  having  the  condition.  It  is 
estimated that 8–43% of those affected have type 2 diabetes (CDC 
2005a). To examine the prevalence of diabetes among children 
and adolescents in the US, a 5-year study, SEARCH for Diabetes 
in Youth, has been initiated by the Centers for Disease Control 
and Prevention (CDC) and the National Institutes of Health.
Type 2 diabetes is most commonly observed in American Indian, 
African American, Asian, and Hispanic/Latino youths. However, 
the  obesity  epidemic  and  a  sedentary  lifestyle  are  thought  to 
be  contributing  factors.  Generally,  children  and  adolescents 
diagnosed with type 2 diabetes are between 10 and 19 years old, 
obese, and have insulin resistance and a strong family history of 
type 2 diabetes (Bloomgarden 2004; CDC 2005b). 
Medical and socioeconomic burden of type 2 diabetes
Type  2  diabetes  is  associated  with  significant  morbidity  and 
mortality  because  of  the  resulting  complications.  Diabetes  is 
the  leading  cause  of  end-stage  renal  disease,  accounting  for 
44% of new cases and is the leading cause of blindness in the 
Western world (CDC 2003). People with diabetes are also likely to 
have a clustering of cardiovascular risk factors such as obesity, 
hypertension, and dyslipidemia, which is often referred to as the 
“metabolic syndrome” (Kahn et al. 2005). Individuals with diabetes 
are  two  to  four  times  more  likely  to  develop  cardiovascular 
disease and have a greater risk of heart attack or stroke than 
individuals without diabetes (IDF 2005a). Indeed, a recent meta 
analysis of prospective cohort studies in patients with diabetes 
showed that hyperglycemia is associated with an increased risk 
of cardiovascular disease (Selvin et al. 2004).
There is also increasing evidence that cardiovascular risk factors 
are more prevalent in individuals with IFG or IGT compared with 
those with normal glucose levels, and that these individuals have 
an increased risk of cardiovascular disease and death (Coutinho et 
al. 1999; DECODE Study Group 2001; Saydah et al. 2001). Recent 
data have shown that abnormal glucose tolerance is a strong risk 
factor for future cardiovascular events after myocardial infarction 
(Bartnik et al 2004). In addition, the presence of cardiovascular 
disease risk factors explains the relationship between prediabetes 
and the development of chronic kidney disease (Fox et al. 2005).
These complications place a huge burden on healthcare services. 
It is estimated that the total direct and indirect expenditure for 
diabetes in the US alone in 2002 was $US132 billion (Hogan 
et al. 2003). The European Cost of Diabetes in Europe – type 
2  (CODE-2)  study  estimated  that  three  times  the  healthcare 
resources  are  spent  on  treating  the  complications  of  type  2 
diabetes than those spent on controlling the disease before the 
onset of complications (Jonsson 2002). Hospitalization accounted 
for  over  50%  of  the  total  cost.  In  contrast,  management  of 
glucose control with oral drugs and insulin accounted for only 7% 
of healthcare costs. It is evident that preventing the development 
of type 2 diabetes complications could have a beneficial effect on 
the huge economic and healthcare burden of type 2 diabetes.
The UK Prospective Diabetes Study (UKPDS) 41 compared the 
cost effectiveness of intensive blood glucose control (sulfonylurea 
or  insulin)  with  conventional  glucose  control  (primarily  diet) 
in patients with type 2 diabetes (Gray et al. 2000). This study 
showed that although intensive blood glucose control significantly 
increased treatment costs, it substantially reduced the cost of 
complications and increased the time free of complications.
The role of incretin hormones in the pathophysiology of  
type 2 diabetes
Type  2  diabetes  is  a  complex  metabolic  disease  that  has  a 
multifactorial  pathogenesis  (Stumvoll  et  al.  2005).  Factors 
involved in the development and progression of type 2 diabetes 
include insulin resistance, reduced pancreatic beta-cell response, 
and inappropriately elevated glucagon levels. These in turn can 
be  affected  by  secondary  factors  such  as  overeating,  lack  of 
exercise, liver damage, hyperlipidemia, and impaired secretion 
of incretin hormones.
Beta-cell dysfunction is a major factor in the pathogenesis of type 
2 diabetes. Insulin from the pancreas normally reduces glucose 
output by the liver, enhances glucose uptake by skeletal muscle, 
and  suppresses  fatty  acid  release  from  fat  tissue.  Individuals 
develop insulin resistance in peripheral tissues and to maintain 
normal glucose levels pancreatic beta cells increase the amount 
of insulin they produce. However, over time there is a progressive 
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deterioration of pancreatic beta-cell function and these cells are 
unable to meet the demand for further increases in insulin levels, 
resulting  in  elevated  glucose  levels  and  subsequently  type  2 
diabetes (Stumvoll et al. 2005). It has been suggested that there 
is approximately a 50% loss of beta-cell function in patients with 
newly diagnosed type 2 diabetes (Turner et al. 1999). Furthermore, 
it has been shown that beta-cell response continues to decline 
(by as much as 4% per year) despite the use of insulin or oral 
glucose-lowering drugs (Holman 1998).
Glucagon is a hormone that stimulates the release of glucose from 
the liver during fasting to maintain normal glucose homeostasis. 
During periods of hyperglycemia glucagon secretion is suppressed. 
In patients with type 2 diabetes, glucagon concentrations are 
elevated  resulting  in  increased  hepatic  glucose  output  and 
postprandial glucose spikes (excursions).
The  role  of  the  incretins,  glucagon-like  peptide  (GLP-1)  and 
glucose-dependent  insulinotropic  polypeptide  (GIP),  in  the 
regulation of postprandial insulin secretion have recently been 
elucidated (Holst & Gromada 2004). GLP-1 is an incretin hormone 
secreted  into  the  bloodstream  from  endocrine  cells  located 
in the intestinal mucosa in response to a meal. It mediates its 
insulintropic  activity  via  GLP-1  receptors  on  pancreatic  beta 
cells and other tissues. The biological activities of GLP-1 include 
mediating glucose-dependent insulin secretion; suppression of 
postprandial glucagon secretion; regulation of gastric emptying; 
and suppression of appetite leading to reduction of food intake 
(Nauck et al. 1996; Zaunder et al. 2002). In individuals with type 
2 diabetes or IGT, the release of GLP-1 in response to a meal 
is  defective,  resulting  in  reduced  circulating  concentrations  of 
postprandial GLP-1 and a blunted insulin secretory response to 
food intake (Nauck et al. 1986). The action of GLP-1 is inactivated 
by the enzyme DPP-4.
Current therapy options 
Initially,  patients  with  type  2  diabetes  may  be  able  to  control 
their blood glucose levels with diet and exercise alone. However, 
many  people  with  diabetes  progress  to  require  antidiabetic 
medications.  Currently,  there  are  five  classes  of  oral  glucose-
lowering drugs available that may be used as a monotherapy 
or in combination. The mechanism of action and the risks and 
benefits of each of these therapy classes are indicated in Fig. 1 
and Table 2, respectively. 
The choice of antidiabetic medication is a complex decision that 
requires several factors to be taken into consideration, therefore 
a decision is often made on a case by case basis. 
Metformin is widely regarded as the drug of choice for patients 
with type 2 diabetes (IDF 2005b), especially for people who are 
overweight or obese. Indeed, the UK National Institute for Health 
and Clinical Excellence (NICE) guidelines recommend metformin 
as a first-line therapy option for the treatment of type 2 diabetes 
(NICE 2002) (Table 2). In comparison, the European Diabetes Policy 
Group (EDPG) guidelines, The American Association of Clinical 
Endocrinologists (AACE) guidelines, and the ADA guidelines do 
not specify their recommendation for first-line therapy with oral 
glucose-lowering drugs (EDPG 1999; AACE 2002; ADA 2005). With 
the continuous deterioration of glucose control over time, the use 
of combination therapy is recommended and many combination 
preparations are available. After the failure of multiple oral agents, 
people with diabetes additionally require insulin therapy. 
The aims of treatment with currently available antidiabetic agents 
are to control hyperglycemia and to reduce cardiovascular risk 
and prevent the development of complications. Recent European, 
UK, and US guidelines for type 2 diabetes recommend glycemic 
targets, with a glycated hemoglobin A1c (HbA1c) target range below 
6.5–7.5%  (EDPG  1999;  AACE  2002;  NICE  2002;  ADA  2005). 
However, the recently completed Action to Control Cardiovascular 
Risk in Diabetes (ACCORD) study in patients with type 2 diabetes 
revealed  increased  mortality  with  treatment  to  get  HbA1c  levels 
below 6% (ACCORD Study Group 2008). The AACE have published 
a series of road maps that suggest treatment algorithms to achieve 
AACE glycemic goals for patients with type 2 diabetes (HbA1c ≤6.5%) 
naïve to therapy or those previously treated with monotherapy or 
combination therapy (AACE 2005; Jellinger et al. 2007). 
Unmet needs
Long-term glycemic control
The  AACE  has  reported  that  67%  of  individuals  with  type  2 
diabetes  do  not  have  adequately  controlled  blood  glucose 
(AACE  2005).  Furthermore,  the  National  Health  and  Nutrition 
Examination Survey (NHANES III) has reported that from 1998 
to 2000 the frequency of poor glycemic control increased among 
US adults with type 2 diabetes (Koro et al. 2004).
In general, for every 1.0% unit reduction in HbA1c, the risk of 
developing  microvascular  diabetic  complications  is  reduced 
by 40% (CDC 2003). The UKPDS demonstrated that the risk of 
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Fig.1 |   Mechanism  of  action  of  current  oral  glucose-lowering 
drugs (reprinted from Stumvoll et al. 2005, with permission 
from  Elsevier).  DPP-lV,  dipephidyl  peptidase  lV;  GLP-1 
glucagon-like peptide 1; NEFA, nonesterified fatty acid.Vildagliptin | place in therapy review
developing, and the progression of, microvascular complications 
are substantially reduced with intensive blood glucose control 
(HbA1c  approximately  7%)  (UKPDS  1998a,b).  Most  of  the 
commonly  used  oral  glucose-lowering  drugs  are  only  able  to 
reduce HbA1c by approximately 1% (Kimmel & Inzucchi 2005). 
This reduction is not sufficient for patients who have HbA1c levels 
much greater than the recommended target. 
Long-term glycemic control is difficult to sustain with oral glucose-
lowering drugs. One of the main reasons for the lack of long-term 
glycemic  control  with  oral  medications  is  that  they  target  the 
tissue abnormalities of the disease (i.e. sensitize specific tissues 
to the effects of insulin or enhance the insulin-producing activity of 
the pancreas) rather than treating the underlying causes of these 
abnormalities, which is the declining function of pancreatic beta 
cells that results in a reduction in endogenous insulin secretion. 
Antidiabetic medications are required that can preserve beta-cell 
function and prevent continuing loss and disease progression. 
Despite the ability of insulin to achieve tight glycemic control, 
physicians  and  people  with  diabetes  are  reluctant  to  use  it   
to  treat  type  2  diabetes  until  after  the  failure  of  multiple  oral 
glucose-lowering  drugs.  This  is  partly  due  to  the  burden  of 
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Advantages Disadvantages UK Guidelines (NICE 2002)
Biguanide (metformin)  Only agent associated with potential 
weight loss
Modest lowering of lipid levels
Improvements in fibrinolysis, 
inflammatory markers, and  
endothelial function
Prevents development of T2D in patients 
with IGT
Relatively inexpensive
GI adverse effects common – minimized by 
slow titration
Rare risk of lactic acidosis limits its use in 
contraindicated patients e.g. patients with 
impaired renal function
Recommended as a first-line glucose-
lowering therapy in patients whose blood 
glucose is inadequately controlled using 
lifestyle intervention alone
Insulin secretagogues 
(sulfonylureas)
Relatively inexpensive Drug interactions
Weight gain
Hypoglycemia – requires self-monitoring of 
blood glucose by the patient
Potential effect on myocardial ischemic 
preconditioning
First-line therapy if the patient is not 
overweight or metformin is not tolerated or 
contraindicated
Use in combination with metformin in 
overweight or obese patients when glucose 
control becomes unsatisfactory
Fast-acting insulin 
secretagogues 
(meglitinides)
Rapid onset and shorter duration 
of action than SUs due to more 
physiologically appropriate control of 
postprandial glucose levels 
Drug interactions
Weight gain – to a lesser degree than SUs
Less risk for hypoglycemia than SUs
Cost is higher than SUs
More frequent dosing schedule than most 
agents – must be taken shortly before  
each meal
Thiazolidinediones 
(glitazones/PPAR- 
gamma agonists)
Beneficial effects on cardiovascular risk 
determinants: cytokines, inflammatory 
markers, lipids, blood pressure, 
endothelial function 
Reduced insulin resistance
Can be used in patients with reduced 
renal function
Weight gain
Edema
ADA/AHA and FDA recommend that 
glitazones are not used in patients with 
advanced heart failure symptoms (class III 
or IV NYHA classification)
Increased risk of edema and cardiac failure 
in combination with insulin
Relatively high cost
Offered as combination therapy if unable 
to take, or if HbA1c remains unsatisfactory 
with, metformin and insulin secretagogues 
as combination therapy
Alfa-glucosidase inhibitors STOP-NIDDM trial demonstrated 
reduced risk of myocardial infarction with 
acarbose 
Delay/prevent the development of T2D
Do not cause weight gain
No clinically significant drug interactions
GI adverse effects e.g. abdominal bloating 
and cramping
Less efficacious than other classes
Relatively high cost
Acarbose considered as alternative when 
unable to use other oral drugs
Insulin Ability to achieve tight glycemic control
Newer noninjectable formulations 
becoming available
Hypoglycemia
Weight gain
Daily injections
Self-monitoring (cost and convenience)
Offered when inadequate blood glucose 
control on optimized oral drugs
ADA, American Diabetes Association; AHA, American Heart Association; GI, gastrointestinal; HbA1c, glycated hemoglobin A1c; IGT, impaired glucose tolerance; NICE, National Institute for Health 
and Clinical Excellence; NYHA, New York Heart Association; PPAR, peroxisome proliferators-activated receptor; STOP-NIDDM, noninsulin dependent diabetes mellitus; SU, sulfonylurea; T2D, 
type 2 diabetes.
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multiple daily injections that are associated with poor patient 
compliance. Therefore, there is a need for oral medications that 
can achieve similar prolonged glycemic control to that of insulin. 
Furthermore, the emerging epidemic of type 2 diabetes in children 
and adolescents presents a new challenge, as this population will 
have a lifetime risk of complications and may require effective 
glycemic control over a prolonged period of time.
Safety and tolerability
Current treatments for type 2 diabetes are also often limited by 
their  contraindications  and  side-effect  profile  that  may  affect 
patient compliance and quality of life (Table 2). 
One  of  the  most  common  side  effects  with  sulfonylureas, 
thiazolidinediones,  and  insulin  is  weight  gain.  The  UKPDS   
33 study demonstrated that weight gain was significantly higher 
(mean 2.9 kg) in patients with type 2 diabetes receiving blood 
glucose  control  with  sulfonylureas  or  insulin  compared  with 
conventional treatment with diet (P<0.001) (UKPDS 1998a). This 
is of particular concern given that people with diabetes are often 
overweight before they commence therapy.
Another common side effect of the sulfonylureas and insulin is 
hypoglycemia. Regular self-monitoring of blood glucose levels 
by fingertip glucose measurements is required to try and avoid 
hypoglycemic  events.  However,  this  extensive  monitoring  is 
inconvenient to the patient and incurs extra costs. 
Finally, agonists of peroxisome proliferators-activated receptor 
(PPAR) gamma have been associated with fluid retention and 
concerns over cardiac failure, and metformin is associated with 
gastrointestinal  intolerance  and  is  contraindicated  in  patients 
with renal impairment or poor left ventricular function due to the 
risk of lactic acidosis.
Diabetes prevention
An emerging concept is the earlier treatment of glucose control 
in the prediabetes state. Recent clinical trials have shown that 
the progression of IGT to type 2 diabetes can be delayed or 
prevented.  These  trials  demonstrated  that  in  patients  with 
IGT,  lifestyle  intervention  (weight  loss  and  modest  exercise), 
treatment with the weight loss agent orlistat, or treatment with 
antidiabetic medications (metformin or acarbose) can reduce the 
risk of developing type 2 diabetes by 25–58% (Pan et al. 1997; 
Tuomilehto et al. 2001; Chiasson et al. 2002; Knowler et al. 2002; 
Torgerson et al. 2004). 
The  ADA  recommends  screening  men  and  women  aged   
≥45  years,  particularly  those  with  a  body  mass  index  (BMI)   
≥25 kg/m2 every 3 years to detect IGT or IFG (ADA/ NIDDKD 2002). 
Currently, it is recommended that patients diagnosed with IGT or 
IFG are given counseling on weight loss and increasing physical 
activity. The ADA and National Institute of Diabetes, Digestive 
and Kidney Disease (NIDDKD) have suggested that additional 
research is required to determine the cost effectiveness of drug 
therapy  as  a  preventative  measure  (ADA/NIDDKD  2002).  No 
antidiabetic drugs are currently licensed for use in individuals with 
prediabetes and existing medications have several disadvantages 
including unwanted side effects. Therefore, there may be a need 
for further treatments to delay or prevent the progression of IGT to   
type 2 diabetes.
Addressing unmet need: new classes of  
antidiabetic medications
To address some of these unmet needs in patients with type 
2 diabetes, new classes of noninsulin antidiabetic drugs been 
developed, including the dual PPAR agonists (e.g. muraglitizar, 
subsequently  discontinued),  amylin  analogs  (e.g.  pramlintide 
acetate,  an  injectable  adjunct  to  insulin),  incretin  mimetics 
(GLP-1 analogues), and the DPP-4 inhibitors, that act as incretin 
enhancers.  In  addition,  a  number  of  alternative  methods  of 
delivery of insulin are being studied. 
Incretin mimetics and DPP-4 inhibitors address the need to act 
on the underlying disease rather than on its symptoms. They 
enhance  glucose-dependent  insulin  secretion  by  pancreatic 
beta cells, and consequently there is little risk of hypoglycemia. 
They also suppress elevated glucagon secretion and increase 
satiety. It has been hypothesized that they may restore beta-cell 
sensitivity to glucose, which could mean that they may be able 
to delay the onset of type 2 diabetes, slow its progression, and 
reduce its cardiovascular and metabolic complications (Holst & 
Gromada 2004). 
The GLP-1 analog exenatide (Byetta®; Amylin Pharmaceuticals 
and Eli Lilly) was the first in this new class of diabetes treatment 
to be approved by the FDA in June 2005. It is approved as an 
adjunctive therapy in patients with type 2 diabetes who have not 
achieved adequate control on metformin and/or a sulfonylurea. 
All GLP-1 analogs are injectable, which may pose a barrier to 
their use as many doctors and people with diabetes are reluctant 
to use injected therapies. 
A review of the dual-PPAR agonists, amylin analogs, and GLP-1 
analogs is beyond the scope of this article, and therefore, these 
drugs will not be discussed in further detail.
DPP-4 inhibitors
Vildagliptin (Galvus) is one of a new class of DPP-4 inhibitors   
that  was  approved  for  use  in  type  2  diabetes  in  the  EU  in   
February  2008.  Other  DPP-4  inhibitors  include  sitagliptin 
phosphate (Januvia®; MRK-0431; Merck Sharp & Dohme/Merck   
&  Co.  Inc),  which  was  approved  in  the  US  in  2006,  and   
saxagliptin  (BMS-477118;  Bristol-Myers  Squibb).  Inhibition 
of DPP-4 delays the degradation of GLP-1 therefore reducing 
glycemia, sustaining insulin levels, and reducing glucagon levels 
in  patients  with  type  2  diabetes  (Ahrén  et  al.  2004b).  DPP-4 
inhibitors were developed to meet existing unmet needs in the 
treatment of type 2 diabetes, and an ideal agent would possess 
the following attributes: good glycemic control, low incidence 
of  hypoglycemia,  beta-cell  preservation  and  improvement  in 
beta-cell function, no weight gain, oral route of administration, 
and good tolerability with minimal gastrointestinal events. One 
of the main advantages of DPP-4 inhibitors, in contrast to the 
GLP-1 agonists, will be their mode of administration, which is 
via the oral route, and may lead to higher levels of adherence   
to therapy. Vildagliptin | place in therapy review
Clinical evidence with vildagliptin 
In-vitro studies have shown that vildagliptin is a potent, reversible, 
competitive inhibitor of human and rat DPP-4, with high selectivity 
for DPP-4 over other peptidase enzymes (Hughes et al. 2002; 
Villhauer et al. 2003; Brandt et al. 2005). In vivo, vildagliptin has 
been shown to inhibit plasma DPP-4 activity in rats (Villhauer et 
al. 2003) and in cynomolgus monkeys for up to 10 hours (Hughes 
et al. 2002). 
In  obese,  insulin-resistant  cynomolgus  monkeys,  vildagliptin 
treatment for 10 weeks significantly (P<0.05) reduced HbA1c and 
fasting plasma insulin (Dardik et al. 2003a). Plasma fibrinogen 
and plasminogen activator inhibitor-1 (PAI-1), two thrombogenic 
risk  factors,  were  also  significantly  (P<0.05)  reduced  during 
vildagliptin treatment (Dardik et al. 2003a). Acute administration 
of  vildagliptin  significantly  (P<0.05)  delayed  gastric  emptying 
(Dardik et al. 2003b), although this was unaffected in 14 patients 
with  type  2  diabetes  given  vildagliptin  50  mg  twice  daily  for   
10 days (Vella et al. 2007).
A  study  in  obese  Zucker  rats  suggests  that  pioglitazone  and 
vildagliptin may have synergistic effects. When coadministered, 
pioglitazone and vildagliptin increased the glucose clearance rate 
after an oral glucose tolerance test, but neither drug alone had 
this effect (Burkey et al. 2002).
Oral  administration  of  vildagliptin  improved  glucose  tolerance 
in various animal models of diabetes, including obese Zucker 
rats (Villhauer et al. 2003), obese, insulin-resistant cynomolgus 
monkeys (Dardik et al. 2003b), and ob/ob mice (Mika et al. 2003). 
Chronic dosing in obese Zucker rats produced similar effects 
to those of acute dosing, and vildagliptin had no effect on the 
animals’ bodyweight (Burkey et al. 2005). 
There  is  some  evidence  from  animal  studies  that  vildagliptin 
may  have  beneficial  effects  on  beta-cell  function.  A  study  in 
mice  showed  that  the  improvement  in  glucose  tolerance  was 
paralleled by an increase in glucose-stimulated insulin secretion 
from isolated islet cells, and was lost in transgenic mice with 
a  defect  in  the  islet  beta-cell  response  to  glucose  (Ahrén  et 
al. 2005a). Vildagliptin has also been shown to increase beta-
cell mass in newborn rats, apparently by stimulating beta-cell 
genesis and inhibiting beta-cell apoptosis (Duttaroy et al. 2005a).   
A  separate  study  in  mice  showed  that  vildagliptin  improved 
glucose  tolerance  in  mice  subjected  to  streptozocin-induced 
beta-cell  damage,  but  in  this  case  there  was  no  effect  on 
apoptosis and the effect appeared to be mediated via enhanced 
differentiation  of  pancreatic  progenitor  cells  (Duttaroy  et  al. 
2005b). However, vildagliptin was unable to prevent progression 
of diabetes in the ZDF rat, a model of rapidly-developing diabetes 
(Rolin et al. 2004).
Vildagliptin’s  major  antidiabetic  mechanism  of  action  appears 
to  be  an  enhancement  of  glucose-stimulated  insulin  release, 
mediated via an increase in GLP-1 levels (Burkey et al. 2005; 
Holst & Deacon 2005). It has also been argued that increased 
GLP-1  may  not  be  the  only  mediator  of  the  clinical  effects 
of  DPP-4  inhibitors,  and  that  other  neuropeptides  may  be 
implicated (Nauck & El-Ouaghlidi 2005). Recently, however, it has 
been shown that insulin secretion stimulated by the neuropeptide 
pituitary adenylate cyclase-activating peptide was unaffected by 
vildagliptin, which appears to act by prolonging the half life of   
L- and K-cell derived incretin hormones (Hjøllund et al. 2007).
The clinical evidence on vildagliptin published to date is mainly 
concerned  with  disease-oriented  outcomes  (such  as  HbA1c, 
blood glucose, and insulin levels), and patient-oriented evidence 
on weight gain and adverse events. 
Effects on glycated HbA1c
HbA1c is an established measure of glycemic control. Evidence 
shows that treatment for up to 52 weeks with vildagliptin at doses 
of 50 or 100 mg/day is effective in reducing HbA1c (Tables 3 and 4). 
The mean reduction in HbA1c with vildagliptin was typically up to   
1 percentage point (Table 3). As discussed earlier (Unmet needs 
section), most of the commonly used oral glucose-lowering drugs 
are also able to reduce HbA1c by approximately 1 percentage 
point.  One  early  study  showed  that  addition  of  vildagliptin   
50 mg/day to metformin treatment resulted in improved glycemic 
control at 12 weeks compared with metformin alone (Ahrén et 
al. 2004a; Table 4). An optional 40-week extension to this study 
provided limited evidence that adding vildagliptin 50 mg/day to 
metformin treatment may help to maintain long-term glycemic 
control. There was a slight increase in HbA1c during the extension 
phase,  but  this  was  less  in  the  patients  receiving  vildagliptin 
plus metformin than in the patients receiving metformin alone, 
and was not statistically significantly different from zero (Ahrén 
et al. 2004a; Table 4). More robust evidence has substantiated 
the  beneficial  effects  of  adding  vildagliptin  to  patients  whose 
diabetes is poorly controlled by metformin alone. After 24 weeks, 
HbA1c was significantly improved by vildagliptin 50 or 100 mg/
day  compared  with  placebo  in  patients  receiving  metformin   
≥1.5  g/day  (Bosi  et  al.  2007;  Dejager  et  al.  2007b;  Table  4). 
Vildagliptin  50  mg  once  or  twice  daily  also  caused  a  further 
reduction in HbA1c of 0.7% compared with placebo in patients 
taking glimepride 4 mg once daily (Garber et al. 2007a; Table 4). 
Similarly, adding vildagliptin 50 mg twice daily reduced HbA1c 
compared with placebo in patients poorly controlled on insulin 
therapy after 24 weeks (Fonseca et al. 2007; Table 4). Patients 
receiving  placebo  were  switched  to  vildagliptin  50  mg  once 
daily  and  after  a  further  28  week  extension  HbA1c  decreased 
significantly by 0.4% (Fonseca et al. 2006).
The percentage of patients reaching a target of <7.0% HbA1c 
was  consistently  in  the  range  40–47%  with  vildagliptin  at   
50 or 100 mg/day, compared with only up to 23% with placebo 
(Tables 3 and 4). It appears that 25 mg/day is little more effective   
than  placebo,  and  that  50  mg/day  and  100  mg/day  have 
approximately similar effectiveness (Tables 3 and 4). However,   
in  patients  with  a  higher  baseline  HbA1c  (>8.0%)  the  effect  of   
vildagliptin  100  mg  given  either  as  a  single  dose  or  as  50  mg 
twice  daily  was  greater  than  that  of  vildagliptin  50  mg  once 
daily  (Dejager  et  al.  2007a;  Pi-Sunyer  et  al.  2007).  Similarly,   
the  reduction  in  HbA1c  was  greater  in  patients  with  higher   
(mean  8.5%)  versus  lower  (mean  7.5%  baseline  HbA1c  with   
vildagliptin  25  mg  twice  daily  (Pratley  et  al.  2006).  Nearly 
four  times  as  many  patients  achieved  HbA1c  <7.0%  when 
vildagliptin  was  added  to  metformin,  and  nearly  half  as 
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many  again  when  vildagliptin  100  mg  once  daily  was 
combined  with  pioglitazone  30  mg  once  daily  compared  with   
either  agent  alone  (Rosenstock  et  al.  2007a;  Table  3).  Fewer   
patients with a higher baseline HbA1c (>8.5%) achieved the target   
of  <7.0%  when  vildagliptin  50  or  100  mg/day  was  added  to   
metformin  compared  with  those  with  intermediate  (7.9–8.5%) 
baseline  levels  (7.5%  and  16.3%  versus  22.2%  and  31.4%)   
(Bosi et al. 2007).
Although a similar reduction in HbA1c was achieved, vildagliptin 
50 mg twice daily was not found to be noninferior to metformin 
2 g daily (Goeke et al. 2006; Schweizer et al. 2007; Table 3). 
Vildagliptin appears to be as effective as pioglitazone (Baron et 
al. 2006; Garber et al. 2007b), and rosiglitazone (Rosenstock et 
al. 2007b) at reducing HbA1c (Table 3).
Double-blind, 
placebo-controlled 
RCT, 24 weeks
Placebo + P  
30 mg qd 
(n=157)
Placebo + P 30 mg 
qd –1.4
Placebo + P 30 mg 
qd 43%
Placebo + P 30 mg 
qd –1.9
NR Rosenstock et al. 
2007a
Placebo + V  
100 mg qd 
(n=150)
Placebo + V 100 mg 
qd –1.1 (P<0.001 vs 
V 100 mg qd + P 30 
mg qd)
Placebo + V 100 mg 
qd 43%
Placebo + V 100 mg 
qd –1.3 (P<0.001 vs 
V 100 mg qd + P 30 
mg qd)
NR
V 50 mg qd + 
P 15 mg qd 
(n=139)
V 50 mg qd + P 15 mg 
qd –1.7 (P=0.039 vs 
placebo + P)
V 50 mg qd + P  
15 mg qd 54%
V 50 mg qd + P 15 mg 
qd –2.4 (P=0.022 vs 
placebo + P)
V 50 mg qd + P 15 mg 
qd –3.8 (P=0.024 vs 
placebo + P)b
V 100 mg qd 
+ P 30 mg qd 
(n=146)
V 100 mg qd + P 30 
mg qd –1.9 (P<0.001 
vs placebo + P)
V 100 mg qd + P  
30 mg qd 65%
V 100 mg qd + P 30 
mg qd –2.8 (P<0.001 
vs placebo + P)
V 100 mg qd + P  
30 mg qd –5.2 
(P<0.001 vs placebo 
+ P)b
(P<0.001 vs placebo 
+ V and placebo + P)
Double-blind RCT, 24 
weeks
V 50 mg bid 
(n=459)
V 50 mg bid –1.1 NR V 50 mg bid –1.3 NR Rosenstock et al. 
2007b
R 8 mg qd 
(n=238)
R 8 mg qd –1.3 NR R 8 mg qd –2.3 
(P<0.001 vs V)
NR
Double-blind RCT, 52 
weeks
V 50 mg bid 
(n=526)
V 50 mg bid –1.0 V 50 mg bid 35% V 50 mg bid –0.9 NR Goeke et al. 2006; 
Schweizer et al. 
2007
M 1 g bid 
(n=254)
M 1 g bid –1.4 M 1 g bid 45% M 1 g bid –1.9 
(P<0.001 vs V)
NR
Double-blind, 
placebo-controlled 
RCT, 24 weeks
Placebo + P  
45 mg qd 
(n=138)
Placebo + P 45 mg 
qd –0.3
Placebo + P 45 mg 
qd 14.8%
Placebo + P 45 mg 
qd –0.5
Baron et al. 2006; 
Garber et al. 
2007b
V 50 mg qd + 
P 45 mg qd 
(n=124)
V 50 mg qd + P 45 mg 
qd –0.8 (P=0.001 vs 
placebo)
V 50 mg qd + P 
45 mg qd 28.7% 
(P=0.007 vs placebo)
V 50 mg qd + P  
45 mg qd –0.8
V 50 mg qd + P  
45 mg qd –1.2b,c
V 50 mg bid 
+ P 45 mg qd 
(n=136)
V 50 mg bid + P 45 
mg qd –1.0 (P<0.001 
vs placebo)
V 50 mg bid + P 
45 mg qd 36.4% 
(P<0.001 vs placebo)
V 50 mg bid + P  
45 mg qd –1.1
V 50 mg bid + P  
45 mg qd –1.9 
(P=0.008 vs placebo)b,c
aOf patients with HbA1c ≥7.0% at baseline.
bValue relative to placebo + P.
c2h-postprandial plasma glucose.
bid, twice daily; M, metformin; NR, not reported; P, pioglitazone; qd, once daily; R, rosiglitazone; RCT, randomized controlled trial; V, vildagliptin.
Design Treatment  
and dose 
Outcome Reference
Mean change from 
baseline in HbA1c 
(percentage points)
% patients 
reaching HbA1c 
<7.0%a
Mean change from 
baseline in fasting 
plasma glucose 
(mmol/L)
Mean change 
from baseline in 
4 h-postprandial 
plasma glucose 
(mmol/L)
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   Table 4 |   Effects of vildagliptin on blood glucose and glycosylated hemoglobin (HbA1c) in placebo-controlled studies (all  
level 2 evidence)
Design Treatment  
and dose 
Outcome Reference
Mean change from 
baseline in HbA1c 
(percentage points)
% patients 
reaching HbA1c 
<7.0%a
Mean change from 
baseline in fasting 
plasma glucose 
(mmol/L)
Mean change 
from baseline in 
4 h-postprandial 
plasma glucose 
(mmol/L)
Double-blind, 
placebo-controlled 
RCT, 24 weeks
Placebo  
+ M ≥1.5 g (n=130)
Placebo  
+ M ≥1.5 g +0.2
Placebo  
+ M ≥1.5 g 9.4%
NR NR Bosi et al. 2007; 
Dejager et al. 
2007b
V 50 mg qd  
+ M ≥1.5 g (n=143)
V 50 mg qd  
+ M ≥1.5 g –0.5 
(P<0.001 vs placebo)
NR NR NR
V 100 mg qd  
+ M ≥1.5 g (n=143)
V 100 mg qd  
+ M ≥1.5 g –0.9 
(P<0.001 vs placebo)
V 100 mg qd + 
M ≥1.5 g 35.5% 
(P<0.001 vs 
placebo)
NR NR
Double-blind, 
placebo-controlled 
RCT, 24 weeks
Placebo (n=94) Placebo –0.3 NR Placebo –0.1 NR Dejager et al. 
2007a
V 50 mg qd (n=104) V 50 mg qd –0.8 NR V 50 mg qd –1.0 NR
V 50 mg bid (n=90) V 50 mg bid –0.8 NR V 50 mg bid –0.8 NR
V 100 mg qd (n=92) V 100 mg qd –0.9 NR V 100 mg qd –0.8 NR
(all P<0.01 vs placebo)
Double-blind, 
placebo-controlled 
RCT, 24 weeks
Placebo  
+ G 4 mg qd (n=144)
Placebo  
+ G 4 mg qd 0b
NR Greater decrease with 
V than with placebo at 
(P=0.118)c
NR Garber et al. 
2007a
V 50 mg qd or bid  
+ G 4 mg qd (n=132)
V 50 mg qd or bid  
+ G 4 mg qd –0.7b 
(P<0.001 vs placebo)
NR NR NR
Double-blind, 
placebo-controlled 
RCT, 24 weeks
Placebo (n=88) Placebo 0 Placebo 13.6% Placebo +0.1 NR Pi-Sunyer et al. 
2007
V 50 mg bid (n=84) V 50 mg qd –0.5 V 50 mg qd 25%c V 50 mg qd –0.5 NR
V 50 mg bid (n=79) V 50 mg bid –0.7
(P<0.001 vs placebo)
V 50 mg bid 30.4%
(P<0.01 vs placebo)
V 50 mg bid –1.2
(P<0.001 vs placebo)
NR
V 100 mg bid (n=89) V 100 mg qd –0.8
(P<0.001 vs placebo)
V 100 mg qd 39.1%
(P<0.001 vs 
placebo)
V 100 mg qd –1.1
(P<0.001 vs placebo)
NR
Double-blind, 
placebo-controlled 
RCT, 24 weeks
Placebo + I  
>30 U/day (n=149)
Placebo +  
I >30 U/day –0.2
NR Placebo +  
I >30 U/day –0.8
NR Fonseca et al. 
2007
V 50 mg bid + I  
>30 U/day (n=140)
V 50 mg bid + I  
>30 U/day –0.5 (P=0.01 
vs placebo)
NR V 50 mg bid +  
I >30 U/day –0.2
NR
Double-blind, 
placebo-controlled 
RCT, 12 weeks
Placebo (n=72) Placebo +0.28 NR Placebo +0.13 Placebo +0.2d Kikuchi et al. 
2006; Mimori et 
al. 2006 V 10 mg bid (n=71) V 10 mg bid –0.53 NR V 10 mg bid –0.62 V 10 mg bid 
–3.5d
V 25 mg bid (n=72) V 25 mg bid –0.67 NR V 25 mg bid –0.78 V 25 mg bid 
–3.2d
V 50 mg bid (n=76) V 50 mg bid –0.92 NR V 50 mg bid –1.37 V 50 mg bid 
–3.4d
(all P<0.001 vs placebo) (all P<0.001 vs 
placebo)
(all P<0.001 vs 
placebo)
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Effects on blood glucose 
Most of the published evidence shows that vildagliptin 50 mg/day 
or 100 mg/day is more effective than placebo in reducing both 
fasting plasma glucose and 2 and 4 hours postprandial plasma 
glucose (Tables 3 and 4). In the dose-ranging study, the changes 
from baseline did not reach statistical significance compared with 
placebo (except for the change in 4 hours postprandial glucose 
with vildagliptin 50 mg once daily), but the numerical values were 
broadly consistent with a dose-related effect reaching a plateau 
at 50 or 100 mg/day (Ristic et al. 2005; Table 4). 
Between-group  changes  in  fasting  plasma  glucose  (FPG) 
with  vildagliptin  50  and  100  mg/day  (–0.8  and  –1.7  mmol/L, 
respectively)  and  in  2  hours  postprandial  glucose  (–1.9  and   
–2.3 mmol/L) also showed significant improvements compared 
with placebo in patients receiving metformin ≥1.5 g/day (Bosi et 
al. 2007). Vildagliptin caused a significantly smaller reduction in 
...table continued
Design Treatment  
and dose 
Outcome Reference
Mean change from 
baseline in HbA1c 
(percentage points)
% patients 
reaching HbA1c 
<7.0%a
Mean change from 
baseline in fasting 
plasma glucose 
(mmol/L)
Mean change 
from baseline in 
4 h-postprandial 
plasma glucose 
(mmol/L)
Double-blind, 
placebo-controlled 
RCT, 12 weeks
Placebo (n=28) Placebo –0.6 Placebo NR Placebo +0.23 Placebo +0.2 Pratley et al. 
2006; Pratley & 
Galbreath 2004 V 25 mg bid (n=70) V –0.6
(P=0.0012)
V 47% V –0.9
(P=0.0043)
V –1.7
(P<0.0001)
Double-blind, 
placebo-controlled, 
multicenter RCT,  
12 weeks
Placebo (n=58) NR Placebo 23% Placebo –0.41 Placebo –0.61 Ristic et al. 2005
V 25 mg bid (n=51) NR V 25 mg bid 44% V 25 mg bid –0.44 V 25 mg bid –1.03
V 25 mg qd (n=54) NR V 25 mg qd 28% V 25 mg qd –0.30 V 25 mg qd –1.50
V 50 mg qd (n=53) V 50 mg qd –0.56 
(P=0.003 vs placebo)
V 50 mg qd 40% V 50 mg qd –0.97 V 50 mg qd –2.00 
(P=0.012 vs placebo)
V 100 mg qd (n=63) V 100 mg qd –0.53 
(P=0.004 vs placebo)
V 100 mg qd 46% V 100 mg qd –0.95 V 100 mg qd –1.50
Other doses NSD vs 
placebo
P values NR All doses NSD vs 
placebo
All other doses NSD 
vs placebo
Double-blind, 
placebo-controlled, 
multicenter RCT,  
12 weeks
Placebo (n=51, of 
whom 29 completed 
extension)
At 12 weeks:
V –0.6
Placebo 0.1
(P<0.0001)
In extension study:  
V +0.0128 per month
Placebo +0.0656 per 
month
(P=0.0243)
Placebo 10.7%
V 41.7%
P value NR
Greater decrease with V 
than with placebo at  
12 weeks (P=0.0057)
Greater decrease 
with V than with 
placebo at 12 weeks 
(P<0.0001)
Greater decrease 
with V than with 
placebo at 52 weeks 
(P=0.0001)
Ahrén et al. 
2004a
Optional extension 
for further 40 weeks
V 50 mg qd (n=56, of 
whom 42 completed 
extension)
Greater decrease with V 
than with placebo at  
52 weeks (P=0.031)
All patients were also 
taking stable doses 
of M 1.5–3 g/day
Double-blind, 
placebo-controlled, 
multicenter RCT,  
4 weeks
Placebo (n=19) Placebo –0.15 NR Placebo –0.4 Placebo –0.4 Ahrén et al. 
2004b
V 100 mg qd (n=18) V –0.53 (P<0.001) NR V –1.1 (P=0.037) V –1.9 (P<0.001)
Double-blind, 
placebo-controlled 
RCT, 4 weeks
Placebo (n=20) NR NR Placebo –0.3 NR Ahrén et al. 2003
V 100 mg qd (n=20) NR NR V –1.0 (P<0.05) NR
Double-blind, 
placebo-controlled, 
single center RCT,  
4 weeks
Placebo (n=11) NR NR Greater decrease with V 
than placebo (P<0.05)
NR Mari et al. 2005
V 100 mg bid (n=9) NR NR NR NR
aOf patients with HbA1c ≥7.0% at baseline.
bPlacebo subtracted value.
cResults presented graphically, not stated.
d2 h-postprandial plasma glucose.
bid, twice daily; G, glimepiride; I, insulin; M, metformin; NR, not reported; NSD, not statistically significantly different; qd, once daily; RCT, randomized controlled trial; V, vildagliptin.
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FPG than rosiglitazone (Table 4), suggesting a more sustained 
effect throughout the day (Rosenstock et al. 2007b).
Effects on glucagon, insulin, and GLP-1
As expected from its mechanism of action, evidence consistently 
shows  that  vildagliptin  increases  postprandial  GLP-1  levels 
relative  to  placebo  (Table  5).  Vildagliptin  also  consistently   
lowers  plasma  glucagon  relative  to  placebo,  but  most  of  the 
evidence appears to show little effect on plasma insulin levels 
(Table 5). However, it has been argued that plasma insulin levels 
are not necessarily a direct measure of plasma insulin secretion, 
and that beta-cell function can be improved without appreciable 
changes  in  plasma  insulin  (Mari  et  al.  2005).  Moreover,  this 
observation  probably  reflects  improved  insulin  secretion  and 
sensitivity, shown by the same insulin level in response to lower 
glucose levels. Inhibition of DPP-4 might not be expected to have 
a significant effect on fasting GLP-1 or GIP because incretin release 
depends on nutrient intake. However, there is some evidence from 
a small study that a high dose of vildagliptin, 100 mg twice daily, 
significantly increased GLP-1 and GIP in patients with type 1 (n=11) 
or type 2 (n=9) diabetes after 4 weeks (Kelley et al. 2006).
Effects on beta-cell function
Evidence suggests that vildagliptin can increase the secretion 
of  insulin  in  response  to  glucose,  indicating  an  improvement 
in  beta-cell  function  (Table  6).  The  dose-ranging  study  found 
that  only  the  highest  dose  of  vildagliptin  (100  mg/day)  was 
significantly  superior  to  placebo,  whereas  other  studies  have 
shown statistically significant differences from placebo at lower 
doses (Table 6). However, this may reflect the variety of measures 
used  to  assess  beta-cell  function,  which  makes  it  difficult  to 
compare results across different studies. In patients inadequately 
controlled  with  metformin  ≥1.5  g/day,  the  insulin  secretory 
response increased by 5.2 and 5.7 pmol/min/m2 with vildagliptin 
50 and 100 mg/day, respectively, compared with placebo (Bosi et 
al. 2007). Adding vildagliptin to pioglitazone also improved beta-
cell function (Rosenstock et al. 2007a; Table 6).
Effects on insulin sensitivity
Evidence from one randomized controlled trial (Ahrén et al. 2005b) 
indicates  that  long-term  vildagliptin  treatment  can  increase 
insulin sensitivity during oral glucose intake (Table 7). The same 
study also found that vildagliptin increased the adaptation index 
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Design Treatment and dose  Outcome Reference
Mean change from 
baseline in  
4 h-postprandial plasma 
insulin (pmol/L)
Mean change from 
baseline in 30 min 
postprandial glucagon 
(ng/mL)
Mean change from 
baseline in 30 min 
postprandial GLP-1 
(pmol/L)
Double-blind, placebo-
controlled, multicenter 
RCT, 12 weeks
Placebo (n=58)
V 25 mg bid (n=51)
V 25 mg qd (n=54)
V 50 mg qd (n=53)
V 100 mg qd (n=63)
Placebo –30.1
V 25 mg bid +3.0
V 25 mg qd –48.2
V 50 mg qd +2.8
V 100 mg qd +19.7 
(P=0.022 vs placebo)
All other doses NSD  
vs placebo
NR NR Ristic et al. 2005
Double-blind, placebo-
controlled, multicenter 
RCT, 12 weeks
Optional extension for 
further 40 weeks 
Placebo (n=51, of whom 29 
completed extension)
V 50 mg qd (n=56, of whom 
42 completed extension)
All patients were also taking 
stable doses of metformin 
1.5–3 g/day
NSD between groups at 
12 weeks
Greater increase with V 
than placebo at 52 weeks 
(P=0.015)
NR NR Ahrén et al. 2004a
Double-blind, placebo-
controlled, multicenter 
RCT, 4 weeks
Placebo (n=19)
V 100 mg qd (n=18)
Insulin response to meal 
ingestion NSD between 
groups
Significant reduction in  
V group (P=0.005)
No significant change in 
placebo group
Significant increase in 
V group (P<0.001)
Placebo NR
Ahrén et al. 2004b
Double-blind, placebo-
controlled RCT, 4 weeks
Placebo (n=20)
V 100 mg qd (n=20)
Insulin response to meal 
ingestion NSD between 
groups
Placebo +2
V 12
(P<0.01)
Placebo +0.9
V +4.7
(P<0.001)
Ahrén et al. 2003
Double-blind, placebo-
controlled, single center 
RCT, 4 weeks
Placebo (n=11)
V 100 mg bid (n=9)
NR 3.5 h mean glucagon: 
lower with V than 
placebo but NSD
Greater increase with V 
than placebo in 13.5 h 
mean GLP-1 (P<0.001)
Mari et al. 2005
bid, twice daily; NR, not reported; NSD, not statistically significantly different; qd, once daily; RCT, randomized controlled trial; V, vildagliptin.
   Table 5 | Effects of vildagliptin on plasma insulin, glucagon, and GLP-1 levels (all level 2 evidence).Vildagliptin | place in therapy review
24
© 2008 Core Medical Publishing Limited
Design Treatment and dose  Outcome Reference
Mean change 
from baseline in 
HOMA-Ba
Insulin response 
corrected for 
peak glucose
Insulin secretion 
after meal divided by 
increase in plasma 
glucose
Insulin secretory 
response at  
7 mmol/L glucose 
(pmol/min/m2)
Double-blind, 
placebo-controlled 
RCT, 24 weeks
Placebo + P 30 mg qd 
(n=157)
Placebo + V 100 mg qd 
(n=150)
NR
NR
NR
NR
NR
NR
NR
NR
Rosenstock et al. 
2007a
V 50 mg qd + P 15 mg qd 
(n=139)
NR NR V 50 mg qd + P 15 mg 
qd +8.0 (P=0.046 vs 
placebo + P)
NR
V 100 mg qd + P  
30 mg qd (n=146)
NR NR V 100 mg qd +  
P 30 mg qd +5.5
NR
Double-blind, 
placebo-controlled 
RCT, 24 weeks
Placebo + P 45 mg qd 
(n=138)
V 50 mg qd + P 45 mg qd 
(n=124)
NR  NR Placebo +  
P 45 mg qd +2
V 50 mg qd + P  
45 mg qd +6 (P<0.01 
vs placebo)b
NR Garber et al. 
2007b
V 50 mg bid + P 45 mg 
qd (n=136)
NR NR V 50 mg bid + P  
45 mg qd +7 (P<0.01 
vs placebo)b
NR
Placebo-controlled 
RCT, 52 weeks
Placebo (n=150) NR NR NR NR Scherbaum et al. 
2007
V 50 mg qd (n=156) NR NR NR V 50 mg qd +5 vs 
placebo (P<0.001)
Double-blind, 
placebo-controlled, 
multicenter RCT,  
12 weeks
Placebo (n=58)
V 25 mg bid (n=51)
V 25 mg qd (n=54)
V 50 mg qd (n=53)
V 100 mg qd (n=63)
Placebo –4.3
V 25 mg bid +16.9
V 25 mg qd +2.9
V 50 mg qd +6.4
V 100 mg qd +22.5 
(P=0.007 vs placebo)
All other doses NSD 
vs placebo
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
Ristic et al. 2005
Double-blind, 
placebo-controlled 
RCT, 12 weeks
Placebo (n=28)
V 25 mg bid (n=72)
NR Significant 
increase with 
V vs placebo 
(P<0.05)
NR NR Pratley & 
Galbreath 2004
Double-blind, 
placebo-controlled, 
multicenter RCT,  
12 weeks
Optional extension 
for further 40 weeks 
Placebo (n=51, of whom 
29 completed extension)
V 50 mg qd (n=56, of 
whom 42 completed 
extension)
All patients were also 
taking stable doses of 
metformin 1.5–3 g/day
NR Greater increase 
with V than 
placebo at  
12 weeks 
(P=0.0007) and  
52 weeks 
(P=0.0005)
Greater with V than 
placebo at 12, 24, and 
52 weeks (P<0.05)
NR Ahrén et al. 2004a, 
2005b
Double-blind, 
placebo-controlled, 
single center RCT,  
4 weeks
Placebo (n=11)
V 100 mg bid (n=9)
NR NR NR Greater increase 
with V than 
placebo (P<0.005)
Mari et al. 2005
aDefined as: HOMA-B (homeostasis model of beta-cell function) = [20 x fasting insulin (mU/L)]/(fasting glucose [mmol/L] –3.5).
bData presented graphically.
bid, twice daily; NR, not reported; P, pioglitazone; qd, once daily; RCT, randomized controlled trial; V, vildagliptin.
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(Table 7), which is considered by the authors to be a measure of 
the ability of beta cells to adapt insulin secretion to the prevailing 
insulin sensitivity (Ahrén et al. 2005b).
Effects on bodyweight
Excess bodyweight is a major risk factor in type 2 diabetes (see 
Disease overview section). Thus, it is important that medications 
for the treatment of diabetes should not cause an increase in 
bodyweight. 
Vildagliptin is not associated with significantly more weight gain 
than placebo according to level 1 evidence from a meta analysis; 
there was a small increase of 0.42 kg [95% confidence interval 
(CI): 0.12, 0.72] (Amori et al. 2007). Weight reduction was greater 
with  vildagliptin  compared  with  pioglitazone  or  rosiglitazone 
(mean 1.7 kg difference), but less than that with metformin (mean 
2.2 kg difference). The effects of vildagliptin on bodyweight are 
shown in Table 8. 
Combination with other agents
Some evidence from animal models suggested that pioglitazone 
and  vildagliptin  could  have  synergistic  effects  on  glucose 
clearance after an oral glucose load (Burkey et al. 2002). The 
combination  has  subsequently  been  studied  in  humans.  One 
study investigated the combination in 12 patients with type 2 
diabetes  (Serra  et  al.  2005).  Patients  received  pioglitazone   
45 mg once daily for 8 weeks, and were then randomized to 
receive  add-on  placebo  or  vildagliptin  100  mg  once  daily  for   
28 days, followed by vildagliptin alone for 7 days. Coadministration 
did not alter the pharmacokinetic behavior of either compound, 
but the combination reduced postprandial glucose significantly 
(P<0.05) more than pioglitazone alone (Serra et al. 2005).
A crossover study in 15 patients with type 2 diabetes found that 
coadministration of glyburide 10 mg once daily and vildagliptin 
100 mg twice daily did not modify the peak plasma concentration, 
area-under-the-curve, or half-life of either agent. Two hypoglycemic 
events occurred in patients receiving glyburide alone, but none in 
patients receiving the combination (Barilla et al. 2004). 
A  study  in  16  healthy  volunteers  reported  that  vildagliptin 
significantly enhanced glibenclamide-stimulated insulin secretion, 
but did not increase the risk of reactive hypoglycemia (El-Ouaghlidi 
et al. 2003, 2004).
These  early  studies  have  been  verified  in  larger,  randomized 
placebo-controlled trials. The combination of vildagliptin 50 mg 
once or twice daily plus metformin caused a significant decrease 
of  HbA1c  compared  with  metformin  alone,  and  a  significantly 
greater proportion of patients achieved levels <7.0% (Dejager 
et al. 2007b; Table 3). Similarly, there was a significantly greater 
reduction  in  HbA1c  when  vildagliptin  50  mg  or  100  mg  daily   
was added to pioglitazone 15, 30, or 45 mg daily compared with 
pioglitazone 30 or 45 mg alone (Garber et al. 2007b; Rosenstock 
et al. 2007a; Table 3).
Effects in prediabetes
There is some preliminary evidence that vildagliptin is effective in 
people with prediabetes. In a 12-week randomized trial, vildagliptin 
50 mg once daily (n=90) significantly (P<0.001) increased GLP-1 
and  GIP  compared  with  placebo  (n=89),  and  improved  beta-
cell function (Rosenstock et al. 2007c). Furthermore, vildagliptin 
reduced  prandial  glucose  excursions  by  22%  compared  with 
baseline, and by 32% compared with placebo. Vildagliptin 100 mg 
once daily also improved insulin sensitivity and beta-cell function 
in 22 patients with prediabetes after 6 weeks (Utzschneider et 
al. 2007).
Safety and tolerability
Level  1  evidence  from  a  meta  analysis  of  12  randomized 
controlled trials comparing vildagliptin with placebo (Ristic et al. 
2005; Mimori et al. 2006; Pratley et al. 2006; Pi-Sunyer et al. 
2007; Dejager et al. 2007), metformin with or without placebo 
(Ahrén et al. 2004a; Bosi et al. 2007; Schweitzer et al. 2007), 
pioglitazone  with  or  without  placebo  (Garber  et  al.  2007b; 
Rosenstock  et  al.  2007a),  rosiglitazone  (Rosenstock  et  al. 
2007b), or insulin (Fonseca et al. 2007) revealed that vildagliptin 
was well tolerated with few adverse effects (Amori et al. 2007). 
There was no risk of gastrointestinal adverse effects compared 
with placebo; urinary tract infection and headache were more 
frequent with vildagliptin versus comparator (3.6% versus 1.3%, 
and 6.3% versus 4.4%, respectively). Nasopharyngitis occurred 
in  7.3%  of  vildagliptin  recipients  and  upper  respiratory  tract 
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Table 7 | Effects of vildagliptin on insulin sensitivity (level 2 evidence)
Design Treatment and dose  Outcome Reference
Oral glucose insulin  
sensitivity (mL/min/m2)
Adaptation index (insulin  
secretion x insulin  
sensitivity)
Double-blind, placebo-
controlled, multicenter RCT, 
12 weeks
Optional extension for further 
40 weeks 
Placebo (n=51, of whom  
29 completed extension)
V 50 mg qd (n=56, of whom  
42 completed extension
All patients were also taking 
stable doses of metformin 
1.5–3 g/day
Greater with V than placebo at 
24 and 52 weeks (P<0.05)
Greater with V than placebo at 
12, 24 (P<0.05), and 52 weeks 
(P<0.01)
Ahrén et al. 2005b
qd, once daily; RCT, randomized controlled trial; V, vildagliptin.Vildagliptin | place in therapy review
infection in 6.8%, compared with 7.3% and 8.0%, respectively, 
with comparator. 
Mild to moderate hypoglycemia occurred with the same frequency 
in patients taking vildagliptin (1.4%) or comparator drugs (1.2%) 
(Amori et el. 2007).
Liver function
A  pooled  analysis  of  clinical  trial  data  from  more  than   
8000 patients was submitted by the manufacturer to European 
regulatory authorities in November 2007 following concerns over 
liver function with vildagliptin. Elevations more than three times 
the upper limit of normal levels of aspartate aminotransferase 
and alanine aminotransferase were revealed in 0.86%, 0.34%, 
and 0.21% of patients taking vildagliptin 100 mg once daily, 50 
mg twice daily, and 50 mg once daily, respectively (Anon 2007). 
The  corresponding  rates  were  0.20%  in  approximately  4400 
patients receiving metformin, a thiazolidinedione, a sulfonylurea, 
or placebo, and 0.40% for placebo alone. 
Resource utilization
Type 2 diabetes is a disease with a high social and economic cost, 
and is steadily increasing in prevalence (see Disease overview 
section). The bulk of this cost is attributable to the complications 
of  diabetes.  As  discussed  earlier,  intensive  control  of  blood 
glucose increases short-term costs compared with conventional 
management, but may reduce the long-term complication rate. 
This reduction in complications should offset the additional cost 
of  intensive  blood  glucose  management.  A  new  antidiabetic 
agent that achieves better glycemic control, and in turn lowers 
complication rates, would have the potential to make significant 
savings in the total resource utilization for diabetes management. 
Economic evidence for vildagliptin is not currently available and 
its effect on healthcare resources has not been assessed.
Vildagliptin  has  shown  some  evidence  of  improved  glycemic 
control  (measured  by  HbA1c)  compared  with  placebo,  either   
as monotherapy or as an add-on to metformin (Tables 3 and 4).   
The magnitude of the reduction in HbA1c demonstrated by the 
evidence so far is up to 1 percentage point (Tables 3 and 4),   
comparable  to  that  achieved  with  other  oral  glucose-   
lowering  drugs.  Vildagliptin  improves  beta-cell  function   
(Table  6)  and  insulin  sensitivity  (Table  7),  which  in  turn   
improves control of blood glucose. In theory, since vildagliptin   
acts  by  enhancing  the  physiologic  response  to  ingestion  of   
a  meal,  it  may  provide  finer  control  of  blood  glucose  than  is 
possible with agents such as sulfonylureas or insulin that act 
more directly. 
There  is  evidence  that  glycemic  control  is  maintained  in  the 
long  term  (52  weeks)  with  vildagliptin  used  as  monotherapy   
or in combination with metformin (Ahrén et al. 2004a; Schweizer 
et  al.  2007).  Successful  long-term  glycemic  control  is  an 
important  clinical  benefit,  as  it  should  contribute  to  a  lower 
risk  of  complications,  but  this  needs  to  be  confirmed  by   
further studies.
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Table 8 | Effects of vildagliptin on body weight (all level 2 evidence)
Design Treatment and dose  Mean change from baseline in body weight (kg) Reference
Double-blind RCT, 52 weeks
Double-blind, placebo- 
controlled RCT, 24 weeks
Double-blind, placebo-
controlled, multicenter RCT, 
12 weeks
Double-blind, placebo-
controlled, multicenter RCT, 
12 weeks
Optional extension for further 
40 weeks 
Double-blind, placebo-
controlled, multicenter RCT, 
4 weeks
V 50 mg bid (n=526)
M 1 g bid (n=254)
Placebo + P 45 mg qd (n=138)
V 50 mg qd + P 45 mg qd (n=124)
V 50 mg bid + P 45 mg qd (n=136)
Placebo (n=58)
V 25 mg bid (n=51)
V 25 mg qd (n=54)
V 50 mg qd (n=53)
V 100 mg qd (n=63)
Placebo (n=51, of whom 29 completed 
extension)
V 50 mg qd (n=56, of whom 42 completed 
extension)
All patients were also taking stable doses 
of metformin 1.5–3.0 g/day
Placebo (n=19)
V 100 mg qd (n=18)
V 50 mg bid +0.3
M 1 g bid –1.9 (P<0.001 vs V)
V 50 mg qd + P 45 mg qd +0.1a
V 50 mg bid + P 45 mg qd +1.3 (P=0.003  
vs placebo)a
Placebo –0.73
V 25 mg bid +0.05
V 25 mg qd –0.55
V 50 mg qd +0.04
V 100 mg qd –0.07
All V doses NSD vs placebo
At 12 weeks:
Placebo –0.5
V –0.4
Extension phase:
Placebo –0.2
V –0.2
(P values NR)
Placebo +0.12
V +0.21
NSD vs placebo
Schweizer et al. 2007
Garber et al. 2007b
Ristic et al. 2005
Ahrén et al. 2004a
Ahrén et al. 2004b
aChange versus placebo + P.
bid, twice daily; M, metformin; NR, not reported; NSD, not statistically significantly different; P, pioglitazone; qd, once daily; RCT, randomized controlled trial; V, vildagliptin.Vildagliptin | place in therapy review
While  long-term  glycemic  control  is  clearly  important,  if 
vildagliptin  (and  other  DPP-4  inhibitors)  is  shown  to  have 
disease-modifying effects by protecting against the prolonged 
decline  in  beta-cell  function  that  continues  with  other  drugs, 
this could be of greater potential benefit in people with diabetes. 
Inhibiting disease progression and hence reducing or delaying the 
development of diabetic complications could provide substantial   
economic benefits. 
Evidence is also needed to compare vildagliptin with injected 
insulin in type 2 diabetes. An oral glucose-lowering drug that 
could reduce HbA1c as effectively as insulin, without weight gain 
or  hypoglycemia,  would  have  a  considerable  advantage  over 
injected insulin in terms of patient convenience.
However, direct evidence will be necessary to assess the likely 
impact of vildagliptin on resource utilization.
Patient group/population
Vildagliptin  acts  by  prolonging  the  life  of  GLP-1  and  thereby 
enhancing its effect on beta cells, so vildagliptin relies on the 
patient having an intact GLP-1 response to food and at least some 
beta-cell function. Vildagliptin would therefore not be expected to 
work in people with diabetes with little or no beta-cell function, 
such as those with type 1 diabetes, and these patients have been 
excluded from the trial populations. It is possible that vildagliptin 
may work better in patients with less advanced type 2 diabetes, 
and there is some evidence that it is effective in patients with 
prediabetes (Rosenstock et al. 2007c). 
Patients with significant diabetic or cardiovascular complications 
were excluded from the published studies, so there is no evidence 
relating to the use of vildagliptin in this population with more 
severe disease.
Vildagliptin  has  been  investigated  in  patients  not  previously 
treated for diabetes, and as an add-on to metformin in patients 
with an inadequate response to metformin therapy. All studies 
of  vildagliptin  were  conducted  in  adults  (aged  ≥18  years). 
Pooled analyses indicate that the drug is effective in different 
ethnicities  (Rosenstock  et  al.  2007d)  and  in  elderly  patients 
(Pratley et al. 2007b), and has a tolerability profile similar to that 
of  metformin,  pioglitazone,  and  rosiglitazone  in  patients  with 
moderate renal insufficiency [glomerular filtration rate (GFR) 30 to   
<60 mL/min/1.73 m2), but better than metformin in those with 
mild  dysfunction  (GFR  60  to  <90  mL/min/1.73  m2)  (Thuren  et   
al. 2007).
Thus, the majority of the present evidence base relates to the use 
of vildagliptin in adult patients with type 2 diabetes but without 
diabetic or cardiovascular complications and who may be either 
drug-naïve or who have not responded adequately to metformin 
therapy. Further results may extend this population to patients 
with prediabetes.
Dosage, administration, and formulations
Vildagliptin  (Galvus)  can  be  prescribed  to  patients  with   
type 2 diabetes at a dosage of 50 mg once daily in combination 
with a sulfonylurea, or 50 mg twice daily with metformin or a 
thiazolidinedione  such  as  pioglitazone.  A  100  mg  formulation 
of  vildagliptin  is  available  in  Brazil  and  Mexico.  A  fixed  dose 
combination  of  vildagliptin  50  mg  plus  metformin  850  mg  or 
vildagliptin 50 mg plus metformin 1000 mg (Eucreas®) has also 
been  approved  for  twice-daily  use  in  patients  inadequately 
controlled  with  metformin  alone  or  who  are  already  receiving 
each drug separately. 
Liver  function  tests  should  be  conducted  before  beginning 
treatment with vildagliptin, every 3 months in the first year of 
treatment, and periodically thereafter. Vildagliptin should not be 
used in patients with liver impairment, those with type 1 diabetes, 
patients with moderate to severe renal impairment, or those with 
congestive heart failure. 
Place in therapy
Metformin is currently first line treatment for people with type 
2 diabetes, with sulfonylureas established as second line, until 
newer  agents  such  as  DPP-4  inhibitors  and  PPAR  agonists 
can demonstrate a clear advantage in terms of efficacy, safety, 
disease progression, or cost. 
There is clear evidence of improved glycemic control (measured 
by  HbA1c,  blood  glucose  or  numbers  of  patients  achieving 
HbA1c  <7.0%)  with  vildagliptin  compared  with  placebo, 
either  as  monotherapy  or  in  combination  with  metformin, 
the  thiazolidinediones  pioglitazone  and  rosiglitazone,  or  the 
sulfonylurea glimepride. Since most patients with type 2 diabetes 
ultimately  require  more  than  one  drug  for  effective  glycemic 
control, this evidence indicates a valuable place for vildagliptin in 
combination therapy. The drug is effective in drug-naïve patients, 
those  poorly  controlled  with  current  treatment,  in  the  elderly, 
and in different ethnicities. There is also evidence of improved 
beta-cell  function  and  improved  insulin  sensitivity  compared   
with placebo. 
Vildagliptin was not associated with significantly more weight 
gain than placebo, and is not associated with a higher rate of 
hypoglycemia  (Amori  et  al.  2007).  The  drug  is  well  tolerated 
with  few  adverse  effects.  The  incidence  of  liver  enzyme 
elevations with vildagliptin 50 mg once daily in clinical trials is 
comparable to that seen with metformin, a thiazolidinedione, or 
a sulfonylurea; the incidence with 50 mg twice daily is less than 
that with placebo.
The present evidence base supports the use of vildagliptin in adults 
with type 2 diabetes and no significant diabetic or cardiovascular 
complications. It can be inferred from the drug’s mechanism of 
action that it may be of most benefit in patients in the early stages 
of type 2 diabetes. As some authorities advocate earlier use of 
insulin in people with diabetes at this stage, studies comparing 
vildagliptin with early insulin would be valuable. There is evidence 
that vildagliptin is effective in patients with prediabetes.
The main area where further evidence is required is on the effect 
of  vildagliptin  on  important  patient-oriented  outcomes  such   
as  disease  progression,  impact  on  cardiovascular  risk,  long-
term complications, health-related quality of life, and adherence   
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to therapy. As the majority of the costs of managing diabetes 
are attributable to managing complications, this evidence would 
also be important in assessing the potential economic impact of   
the agent.
In  summary,  vildagliptin  has  shown  evidence  of  improved 
glycemic  control  and  a  potentially  favorable  tolerability  profile 
in  adult  patients  with  type  2  diabetes.  This  has  potential  for 
important clinical and/or economic benefits in the management 
of  diabetes,  as  improved  glycemic  control  is  likely  to  reduce 
the risk of complications and thus improve resource utilization. 
Vildagliptin  could  be  a  useful  option  for  use  in  combination 
therapy in patients with type 2 diabetes. 
Acknowledgements 
The authors declare that they have no conflicts of interest.
References
AACE (American Association of Clinical Endocrinologists). Diabetic Guidelines. 
Endocrine Practice. 2002;8(Suppl 1):41–65.
AACE (American Association of Clinical Endocrinologists). State of Diabetes  
in America. Available at: http://www.stateofdiabetes.com (accessed  
November 8, 2005). 
ACCORD Study Group. Effects of intensive glucose lowering in type 2  
diabetes. N Engl J Med. 2008;358:2545–2559.
ADA (American Diabetes Association) and NIDDKD (National Institute of 
Diabetes, Digestive and Kidney Diseases). The prevention or delay of type 2 
diabetes. Diabetes Care. 2002;25:742–749.
ADA (American Diabetes Association). Standards of medical care in diabetes. 
Diabetes Care. 2005;28(Suppl. 1):S4–S36.
Ahrén B, Landin-Olsson M, Jansson P-A, et al. The DPPIV inhibitor, LAF237, 
reduces fasting and postprandial glucose in subjects with type 2 diabetes over 
a 4 week period by increasing active GLP-1, sustaining insulin and reducing 
glucagon. Diabetes. 2003;52 (Suppl. 1):A15. Abstract 65-OR.
Ahrén B, Mills D, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and  
52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-
treated patients with type 2 diabetes. Diabetes Care. 2004a;27:2874–2880.
Ahrén B, Landin-Olsson M, Jansson P-A, Svensson M, Holmes D, Schweizer 
A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, 
and reduces glucagons levels in type 2 diabetes. J Clin Endocrinol Metab. 
2004b;89:2078–2084.
Ahrén B, Gomis R, Mills D, Schweizer A. The DPP-4 inhibitor, LAF237,  
improves glycemic control in patients with type 2 diabetes (T2DM) inadequately 
treated with metformin. Presented at the American Diabetes Association  
Scientific Sessions, 2004c. Abstract 354-OR. Available at: http://scientificsessions.
diabetes.org/Abstracts/index.cfm (accessed December 12, 2005).
Ahrén B, Winzell MS, Burkey B, Hughes TE. Beta-cell expression of a  
dominant-negative hepatocyte nuclear factor (HNF)-1alfa compromises the 
ability of DPP-4 inhibition to elicit a long-term augmentation of insulin secretion 
in mice. Presented at the American Diabetes Association Scientific Sessions, 
2005a. Abstract 1559-P. Available at: http://scientificsessions.diabetes.org/
Abstracts/index.cfm (accessed December 12, 2005).
Ahrén B, Foley JE, Pacin G, Schweizer A. Improved meal-related beta-cell 
function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor  
vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. 
Diabetes Care. 2005b;28:1936–1940.
Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 
diabetes: systematic review and meta-analysis. JAMA. 2007;298:194–206.
Anon. New Galvus® clinical data reinforces efficacy profile; safety up-
date provided to regulatory agencies. Available at http://cws.huginonline.
com/N/134323/PR/200711/1166139_5_2.html (accessed November 12, 2007).
Barilla D, He Y, Balez S, et al. No pharmacokinetic interactions or acute  
clinical safety issues preclude combination of the DPP-4 inhibitor LAF237 with 
glyburide. Presented at the American Diabetes Association Scientific Sessions, 
2004. Abstract 1967-PO. Available at: http://scientificsessions.diabetes.org/
Abstracts/index.cfm (accessed December 12, 2005).
Baron MA, Rosenstock J, Bassiri B, et al. Efficacy of vildagliptin combined 
with pioglitazone in patients with type 2 diabetes. Presented at the European 
Association for the Study of Diabetes Annual Meeting, 2006. Abstract 0801. 
Available at: http://www.easd.org/ (accessed October 11, 2007).
Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Rydén L. Newly 
detected abnormal glucose tolerance: an important predictor of long-term 
outcome after myocardial infarction. Eur Heart J. 2004;25:1990–1997.
Bloomgarden ZT. Type 2 diabetes in the young: the evolving epidemic.  
Diabetes Care. 2004;27:998–1010.
Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of  
vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes 
inadequately controlled with metformin. Diabetes Care. 2007;30:890–895.
Brandt I, Joossens J, Chen X, et al. Inhibition of dipeptidyl-peptidase IV catalyzed 
peptide truncation by vildagliptin ((2S)-{[3-hydroxyadamantan-1-yl)amino]acetyl]}-
pyrrolidine-2-carbonitrile). Biochem Pharmacol. 2005;70:134–143.
Burkey B, Li X, Bolognese L, et al. Combination treatment of a DPP-IV inhibitor 
NVP-LAF237 with pioglitazone completely normalized glucose tolerance in 
adult obese Zucker rats. Diabetes. 2002;51(Suppl. 2):A338. Abstract 1383-P.
Burkey BP, Li X, Bolognese L, et al. Acute and chronic effects of the  
incretin enhancer vildagliptin in insulin resistant rats. J Pharmacol Exp Ther. 
2005;315:688–695.
CDC (Centers for Disease Control and Prevention). Diabetes Projects, 2005b. 
Available at: http://www.cdc.gov/diabetes/projects/cda2.htm (accessed 
November 7, 2005). 
CDC (Centers for Disease Control and Prevention). Fact Sheet. SEARCH for 
Diabetes in Youth, 2005a. Available at: http://www.cdc.gov/diabetes/pubs/pdf/
search.pdf (accessed November 7, 2005).
CDC (Centers for Disease Control and Prevention). National Diabetes Fact 
Sheet, United States, 2003. General Information. Available at: http://www.cdc.
gov/diabetes/pubs/pdf/ndfs_2003.pdf (accessed November 7, 2005). 
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M;  
STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2  
diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359: 
2072–2077.
Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose 
and incident cardiovascular events. A metaregression analysis of published 
data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes 
Care. 1999;22:233–240.
Dardik B, Schwartzkopf C, Stevens D, et al.The dipeptidyl peptidase IV 
inhibitor NVP-LAF237 improves metabolic control in diabetic and nondiabetic 
cynomolgus monkeys. Diabetes. 2003a;52(Suppl.1):A322. Abstract 1391-P.
Dardik B, Valentin M, Schwartzkopf C, et al. NVP-LAF237, a dipeptidyl  
peptidase IV inhibitor, improves glucose tolerance and delays gastric  
emptying in obese insulin resistant cynomolgus monkeys. Diabetes. 2003b;52 
(Suppl.1):A322. Abstract 1392-P.
DECODE Study Group, the European Diabetes Epidemiology Group. Glucose 
tolerance and cardiovascular mortality: comparison of fasting and 2-hour 
diagnostic criteria. Arch Intern Med. 2001;161:397–405.
Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naïve patients 
with type 2 diabetes: a 24-week, double-blind, randomized, placebo- 
controlled, multiple-dose study. Horm Metab Res. 2007a;39:218–223.
Dejager S, Schweizer A, Couturier A, Pratley RE. Achievement of glycaemic  
targets with vildagliptin. Presented at the European Association for the  
Study of Diabetes Annual Meeting, 2007b. Abstract 0885. Available at:  
http://www.easd.org/ (accessed October 11, 2007).
Duttaroy A, Voelker F, Merriam K, Zhang X, Ren X, Burkey B. The DPP-4 
inhibitor vildagliptin increases pancreatic beta-cell neogenesis and decreases 
apoptosis. Presented at the American Diabetes Association Scientific  
Sessions, 2005a. Abstract 572-P. Available at: http://scientificsessions. 
diabetes.org/Abstracts/index.cfm (accessed December 12, 2005).
28
© 2008 Core Medical Publishing LimitedVildagliptin | place in therapy review
Duttaroy A, Voelker F, Ren X, et al. Head-to-head comparison of the DPP-4 
inhibitor vildagliptin with exendin-4 in a model of pancreatic beta-cell injury. 
Presented at the American Diabetes Association Scientific Sessions, 2005b. 
Abstract 267-OR. Available at: http://scientificsessions.diabetes.org/Abstracts/
index.cfm (accessed December 12, 2005).
EDPG (European Diabetes Policy Group). A desktop guide to type 2  
diabetes. International Diabetes Federation European Region. Diabetic Med. 
1999;16:716–730.
El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Holmes D, Nauck MA.  
Reduced increments in total glucagon-like peptide 1 (GLP-1) and gastric 
inhibitory polypeptide (GIP) in plasma after a single dose of the dipeptidyl 
peptidase-4 inhibitor LAF237 before an oral glucose load in healthy subjects. 
Presented at the European Association for the Study of Diabetes Annual  
Meeting, 2004. Abstract 786. Available at: http://212.144.4.93/easd/ 
UpApplications/UpTables/provisionalprogram/groupviewpage.asp (accessed 
December 12, 2005).
El-Ouaghlidi A, Rehring E, Schweizer A, Holmes D, Nauck M. The dipeptidyl 
peptidase IV inhibitor LAF 237 does not accentuate reactive hypoglycemia 
caused by the sulfonylurea glibenclamide administered before an oral glucose 
load in healthy subjects. Diabetes. 2003;52 (Suppl. 1):A118. Abstract 507-P.
Fonseca V, Dejager S, Albrecht D, Shao Q, Schweizer A. Sustained efficacy 
and reduced hypoglycaemia with vildagliptin added to insulin in patients with 
type 2 diabetes. Presented at the European Association for the Study of  
Diabetes Annual Meeting, 2006. Abstract 0802. Available at: http://www.easd.
org/ (accessed October 11, 2007).
Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition  
of vildagliptin to insulin improves glycaemic control in type 2 diabetes.  
Diabetologia. 2007;50:1148–1155.
Fox CS, Larson MG, Leip EP, Meigs JB, Wilson PW, Levy D. Glycemic  
status and development of kidney disease: the Framingham Heart Study. 
Diabetes Care. 2005;28:2436–2440.
Garber AJ, Camisasca R-P, Jauffret S, Baron MA. Efficacy and tolerability 
of vildagliptin added to a sulfonylurea (SU) in patients with type 2 diabetes 
(T2DM). Presented at the American Diabetes Association Annual Meeting, 
2007a. Abstract 0501-P. Available at: http://scientificsessions.diabetes.org/
Abstracts/index.cfm (accessed October 11, 2007).
Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in  
combination with pioglitazone improves glycaemic control in patients with  
type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo- 
controlled study. Diabetes, Obesity and Metabolism. 2007b;9:166–174.
Goeke B, Schweizer A, Couturier A, LeBeaut A, Dejager S. Sustained efficacy 
and tolerability of vildagliptin monotherapy during one-year treatment of  
drug-naïve patients with type 2 diabetes. Presented at the European  
Association for the Study of Diabetes Annual Meeting, 2006. Abstract 0042. 
Available at: http://www.easd.org/ (accessed October 11, 2007).
Gray A, Raikou M, McGuire A, et al; United Kingdom Prospective Diabetes 
Study Group. Cost effectiveness of an intensive blood glucose control policy 
in patients with type 2 diabetes: economic analysis alongside randomised 
controlled trial (UKPDS 41). BMJ. 2000;320:1373–1378.
Hjøllund KR, Hughes TE, Holst JJ. The dipeptidyl peptidase 4 inhibitor  
vildagliptin has no acute effect on the endocrine secretion in the isolated  
perfused porcine pancreas. Presented at the European Association for the 
Study of Diabetes Annual Meeting, 2007. Abstract 0691. Available at:  
http://www.easd.org/ (accessed March 4, 2008).
Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic costs  
of diabetes in the US in 2002. Diabetes Care. 2003;26:917–932.
Holman RR. Assessing the potential for alpha-glucosidase inhibitors in  
prediabetic states. Diabetes Res Clin Pract. 1998;40(Suppl):S21–S25.
Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic ac-
tions of DPP-IV inhibitors. Diabetologia. 2005;48:612–615.
Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin 
secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 
2004;287:E199–E206.
Hughes TE, Russell ME, Bolognese L, et al. NVP-LAF237, a highly selective 
and long-acting dipeptidyl peptidase IV inhibitor. Diabetes. 2002;51(Suppl. 
2):A67. Abstract 272-OR. 
IDF (International Diabetes Federation). Diabetes Prevelance. 2005a. Available 
at http://www.idf.org/home/index.cfm?node=264 (accessed November 7, 2005).
IDF. Global guideline for type 2 diabetes. 2005b. Available at http://www.idf.
org/home/index.cfm?node=1457 (accessed October 16, 2007).
Jellinger PS, Davidson JA, Blonde L, et al. Road maps to achieve glycemic 
control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. 
Endocr Pract. 2007;13:260–268.
Jonsson B. CODE-2 Advisory Board. Revealing the cost of Type II diabetes in 
Europe. Diabetologia. 2002;45:S5–S12.
Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes Association;  
European Association for the Study of Diabetes. The metabolic syndrome:  
time for a critical appraisal: joint statement from the American Diabetes  
Association and the European Association for the Study of Diabetes. Diabetes 
Care. 2005;28:2289–2304.
Kelley DE, Dunning BE, Ligueros-Saylan M, Holst JJ, Deacon CF, Foley JE. 
Four-week treatment with vildagliptin increases fasting plasma levels of intact 
incretin hormones both in patients with type 1 (T1DM) and type 2 (T2DM)  
diabetes. Presented at the American Diabetes Association Annual Meeting, 
2006. Abstract 1481-P. Available at: http://scientificsessions.diabetes.org/
Abstracts/index.cfm (accessed October 11, 2007).
Kikuchi M, Abe N, Kato M, Terao S, Holmes D, Mimori N. Vildagliptin decreases 
HbA1c after 12 weeks treatment in Japanese patients with type 2 diabetes. 
Presented at the European Association for the Study of Diabetes Annual  
Meeting, 2006. Abstract 0789. Available at: http://www.easd.org/ (accessed 
October 11, 2007).
Kimmel B, Inzucchi SE. Oral agents for type 2 diabetes: an update. Clinical 
Diabetes. 2005;23:64–76.
Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program 
Research Group. Reduction in the incidence of type 2 diabetes with lifestyle 
intervention or metformin. N Engl J Med. 2002;346:393–403.
Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 
2000 among US adults diagnosed with type 2 diabetes: a preliminary report. 
Diabetes Care. 2004;27:17–20.
Mari A, Sallas M, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, 
improves model-assessed beta-cell function in patients with type 2 diabetes.  
J Clin Endocrinol Metab. 2005;90:4888–4894.
Mika A, Stashko M, Lubben T, et al. Acute DPP-IV inhibition minimizes glucose 
and insulin responses to a glucose challenge in a diabetic mouse. Presented at 
the American Diabetes Association Scientific Sessions, 2003. Abstract 1516-P. 
Available at: http://scientificsessions.diabetes.org/Abstracts/index.cfm  
(accessed December 12, 2005).
Mimori N, Terao S, Holmes D. Vildagliptin improves glucose control as  
evidenced by HbA1c after 12 weeks therapy in Japanese patients with type 
2 diabetes. Presented at the American Diabetes Association Annual Meeting, 
2006. Abstract 527-P. Available at: http://scientificsessions.diabetes.org/
Abstracts/index.cfm (accessed October 11, 2007).
Nauck MA, El-Ouaghlidi A. The therapeutic actions of DPP-IV inhibition are not 
mediated by glucagon-like peptide-1. Diabetologia. 2005;48:608–611.
Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2  
(non-insulin dependent) diabetes. Diabetologia. 1986;29:46–52.
Nauck MA, Wollschlager D, Werner J, et al. Effects of subcutaneous  
glucagon-like peptide 1 (GLP-1[7-36 amide]) in patients with NIDDM.  
Diabetologia. 1996;39:1546-1553.
NICE (National Institute for Health and Clinical Excellence). Clinical guidelines 
for type 2 diabetes: Management of blood glucose. September 2002. Available 
at: http://www.nice.org.uk (accessed November 7, 2005).
Pan XR, Li GW, Hu YH, et al; The Da Qing IGT and Diabetes Study. Effects  
of diet and exercise in preventing NIDDM in people with impaired glucose  
tolerance. Diabetes Care. 1997;20:537–544.
Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of 
vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes 
Res Clin Pract. 2007;76:132–138.
Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in 
children and adolescents. J Pediatr. 2005;146:693–700.
29 Core Evidence 2008;3(1)Vildagliptin | place in therapy review
Pratley R, Galbreath E. Twelve-week monotherapy with the DPP-4 inhibitor 
LAF237 improves glycemic control in patients with type 2 diabetes. Diabetes. 
2004;53(Suppl. 2):A83. Abstract 355-OR.
Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week  
monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in 
subjects with type 2 diabetes. Horm Metab Res. 2006;38:423–428.
Pratley RE, Rosenstock J, Pi-Sunyer FX, Couturier A, Schweizer A, Dejager 
S. Efficacy and safety of vildagliptin in the elderly: pooled analysis of 5 
monotherapy studies. Presented at the European Association for the Study of 
Diabetes Annual Meeting, 2007b. Abstract 0887. Available at: http://www.easd.
org/ (accessed October 11, 2007).
Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with  
dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin 
(LAF237) dose response. Diabetes Obes Metab. 2005;7:692–698.
Rolin B, Nygaard H, Wilken M, Kanstrup AB, Carr RD. The novel,  
xanthine-based, DPPIV inhibitor NN7201 and LAF237 improve glucose  
tolerance but do not prevent progression of diabetes in Zucker diabetic fatty 
rats. Presented at the American Diabetes Association Scientific Sessions, 
2004. Abstract 1417-P. Available at: http://scientificsessions.diabetes.org/
Abstracts/index.cfm (accessed December 12, 2005).
Rosenstock J, Baron MA, Camisasca RP, Cressier F, Cautier A, Dejager S. 
Efficacy and tolerability of initial combination therapy with vildagliptin and 
pioglitazone compared with component monotherapy in patients with type 2 
diabetes. Diabetes Obes Metab. 2007a;9:175–185.
Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of 
vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes. 
Diabetes Care. 2007b;30:217–223.
Rosenstock J, Rendell MS, Landin-Olsson M, Foley JE, Rochette E, Baron MA, 
Dejager S. Effects of vildagliptin in subjects with IGT. Presented at the  
American Diabetes Association Annual Meeting, 2007c. Abstract 0505-P.  
Available at: http://scientificsessions.diabetes.org/Abstracts/index.cfm  
(accessed October 11, 2007).
Rosenstock J, Pi-Sunyer FX, Banerji MA, Couturier A, Schweizer A, Dejager S. 
Consistent efficacy and safety of vildagliptin monotherapy across ethnicities. 
Presented at the American Diabetes Association Annual Meeting, 2007d.  
Abstract 2141-PO. Available at: http://scientificsessions.diabetes.org/Abstracts/
index.cfm (accessed October 11, 2007).
Saydah SH, Eberhardt MS, Loria CM, Brancati FL. Subclinical states of glucose 
intolerance and risk of death in the US. Diabetes Care. 2001;24:447–453.
Scherbaum WA, Schweizer A, Mari A, et al. Efficacy and tolerability of  
vildagliptin in drug-naïve patients with type 2 diabetes (T2DM) and mild  
hyperglycemia. Presented at the American Diabetes Association Annual  
Meeting, 2007. Abstract 0503-P. Available at: http://scientificsessions.diabetes.
org/Abstracts/index.cfm (accessed October 11, 2007).
Schweizer A, Couturiert A, Foley JE, Dejager S. Comparison between  
vildagliptin and metformin to sustain reductions in HbA1c over 1 year in  
drug-naïve patients with type 2 diabetes. Diabetic Med. 2007;24:955–961.
Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated 
hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 
2004;141:421–431.
Serra DB, He Y-L, Wang Y, et al. Combination of the DPP-4 inhibitor vildagliptin 
(LAF237) with pioglitazone is safe and well tolerated with no pharmacokinetic 
interaction. Presented at the American Diabetes Association Scientific  
Sessions, 2005. Abstract 2192-PO. Available at: http://scientificsessions. 
diabetes.org/Abstracts/index.cfm (accessed December 12, 2005).
Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of 
pathogenesis and therapy. Lancet. 2005;365:1333–1346.
Thuren T, Byiers S, Mohideen P. Vildagliptin is safe and well tolerated in 
patients with mild or moderate renal impairment. Presented at the European 
Association for the Study of Diabetes Annual Meeting, 2007. Abstract 0881. 
Available at: http://www.easd.org/ (accessed October 11, 2007).
Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the  
prevention of diabetes in obese subjects (XENDOS) study: a randomized  
study of orlistat as an adjunct to lifestyle changes for the prevention of type 
2 diabetes in obese patients. Diabetes Care. 2004;27:155–161. Erratum in: 
Diabetes Care. 2004;27:856.
Tuomilehto J, Lindström J, Eriksson JG, et al; Finnish Diabetes Prevention Study 
Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among 
subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–1350.
Turner RC, Cull CA, Frighi V, Homan R; The UKPDS Group. Glycemic control 
with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes 
mellitus: progressive requirement for multiple therapies (UKPDS49). JAMA. 
1999;281:2005–2012.
UKPDS (UK Prospective Diabetes Study) Group. Effect of intensive  
blood-glucose control with metformin on complications in overweight patients 
with type 2 diabetes (UKPDS 34). Lancet. 1998a;352:854–865.
UKPDS (UK Prospective Diabetes Study) Group. Intensive blood-glucose 
control with sulphonylureas or insulin compared with conventional treatment 
and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 
1998b;352:837–853.
Utzschneider KM, Tong J, Udayasankar J, et al. The dipeptidyl peptidase-4 
(DPP-4) inhibitor vildagliptin improves insulin sensitivity and beta-cell function 
in subjects with impaired fasting glucose. Presented at the American  
Diabetes Association Annual Meeting, 2007. Abstract 0515-P. Available at: 
http://scientificsessions.diabetes.org/Abstracts/index.cfm (accessed  
October 11, 2007).
Vella A, Bock G, Giesler PD, et al. Effects of dipeptidyl peptidase-4 inhibition 
on gastrointestinal function, meal appearance, and glucose metabolism in type 
2 diabetes. Diabetes. 2007;56:1475–1480.
Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-hydroxy-1-adamantyl)amino]
acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable  
dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med 
Chem. 2003;46:2774–2789.
WHO (World Health Organization). Screening for type 2 diabetes. Report of a 
World Health Organization and International Federation Meeting 2003.  
Available at http://www.who.int/diabetes/publications/en/screening_mnc03.pdf 
(accessed November 7, 2005).
Zander M, Madsbad S, Madsen JL, Holst J. Effect of a 6-week course of 
glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell 
function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824–830.
Correspondence: Paul Chrisp, Core Medical Publishing, Mere 
House, Brook Street, Knutsford, Cheshire WA16 8GP, UK or at 
editor@coreevidence.com
30
© 2008 Core Medical Publishing Limited